| *Sponsored
Watching Now: Nasdaq Profile (INBS) Pops Green On Breaking News (Strong Financial Results)
May 13th Greetings, Friend!
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is making moves early Tuesday.
Popping green first thing, INBS could start attracting some serious buzz after dropping breaking news!
Take a look:
Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements
20% sequential quarterly revenue growth and 91% year-over-year quarterly gross pro-fit growth
Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025
35 new accounts and international growth during Q3 bring total active accounts to over 450
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.
The Company delivered a strong quarter of growth in revenue compared to the previous quarter, supported by ongoing expansion across safety-critical industries and steady customer acquisition. Cartridge sales, a key contributor to margin improvement, continue to make up a growing share of income, contributing 58% of total revenue for the fiscal year to March 31, 2025, and strengthening the Company’s recurring revenue model. With 35 new customers added during the quarter and an active customer base now surpassing 450 accounts, INBS remains on track with its plans to scale its commercial footprint and international presence ahead of its expected entry into the U.S. market.
...
“As we expand further into new markets, our focus on growing cartridge adoption, our highest-margin revenue stream, is strengthening the business fundamentals,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “We’ve also seen a notable reduction in losses this quarter, reflecting ongoing improvements in cost control and operational efficiency. To support global scalability, we introduced multilingual functionality across our drug screening system and websites, ensuring our solution is widely accessible, commercially viable, and ready for broader distribution across international markets. We believe these efforts are laying a strong foundation for long-term, sustainable revenue growth.” ...
Read the full article here.
Remember, INBS is a low float idea with roughly 4.72Mn shares.
That means it will be critical to watch for potential volatility after today's huge announcement.
Don't hesitate. Consider (Nasdaq: INBS) for your watchlist and check out my initial report below right now. -----
Let's rewind to this past Friday in case you weren't around...
Pay close attention-because the action with my latest Nasdaq profile was nothing short of electrifying.
Following Thursday’s after-hours close of $.54, that sizzler rocketed to a Friday high of $.8138, setting the market abuzz.
We’re talking about a lightning-fast surge of approx. 50% in a matter of hours-an explosive move that left profile trackers looking for more.
But here’s where it gets even more exciting: I’ve got my eye on a brand-new, under-the-radar profile.
With a low float of fewer than 5Mn shares, a $12 analyst target suggesting over 850% potential upside from Monday's close, and massive May news, this Nasdaq profile may start earning Wall Street's immediate attention.
Consider taking a look at: Intelligent Bio Solutions Inc. (Nasdaq: INBS)
Intelligent Bio Solutions Inc. is rapidly emerging as a leader in the medical technology sector, pioneering non-invasive, real-time point-of-care testing solutions that are reshaping how drug screening and diagnostics are conducted worldwide.
With a focus on pain-free, accessible, and accurate testing, the company is positioned at the forefront of a global movement toward more humane and efficient healthcare technologies.
Company Overview
Founded in 2016 and headquartered in New York, Intelligent Bio Solutions Inc. is committed to leveraging advanced technology to develop transformative solutions that improve quality of life.
The company’s mission is to redefine the approach to testing by delivering pain-free, accessible solutions that drive transformative change across healthcare and workplace safety.
Core Technologies and Products
Intelligent Fingerprinting Drug Testing Solution
At the heart of INBS’s innovation is the Intelligent Fingerprinting Drug Testing Solution.
This system utilizes a patented technology that analyzes sweat collected from the fingertips to detect recent drug use-including cann-a-bis, co-caine, o-piate-s, and me-thamp-heta-mine-within the preceding 16–24 hours.
The process is non-invasive, requiring less than a minute for sample collection and delivering results in under ten minutes.
Key advantages include:
- Dignified, Non-Invasive Collection: No need for blood, urine, or saliva samples, reducing discomfort and privacy concerns.
- Rapid Results: Enables timely decision-making in workplace, clinical, and law enforcement settings.
- Portability and Ease of Use: Designed for use in the field, workplaces, and clinics, with minimal training required.
- Hygienic and Cost-Effective: Reduces biohazard risks and maintenance costs, with annual calibration sufficing for ongoing use.
Regulatory Milestones And U.S. Market Entry
A significant milestone was achieved with the submission of the FDA 510(k) pre-market notification for the Intelligent Fingerprinting Drug Screening System in December 2024.
The company’s clinical studies have demonstrated high sensitivity, specificity, and usability, with performance data showing 94.1% accuracy and pharmacokinetic studies confirming the reliability of fingerprint sweat as a matrix for drug detection.
INBS is on track for a planned expansion into the multi-Bn dollar U.S. market in 2025, targeting a region that accounts for approximately 28% of the global drug screening market.
The rising rates of drug positivity in the U.S. workforce-particularly in safety-sensitive industries-underscore the urgent need for effective, rapid, and non-invasive testing solutions like those offered by INBS.
Intellectual Property and Competitive Position
INBS’s technology is protected by a robust intellectual property portfolio, including six U.S. patents covering the lateral flow test strip, sample collection cartridge, cartridge housing, and buffer clip design.
This IP protection strengthens the company’s competitive position as it prepares for broader commercialization and future product development.
Market Opp. And Future Outlook | 
0 Response to "Watching Now: Nasdaq Profile (INBS) Pops Green On Breaking News (Strong Financial Results)"
Post a Comment